Triple T, a new minimally invasive therapy, could replace adrenal surgery for treating primary aldosteronism, a hidden cause ...

RGGGH introduces RFA machine for cancer and chronic pain management, providing free procedures to patients in need.

The following is a summary of “Therapeutic outcomes and safety of radiofrequency ablation for primary papillary thyroid ...

This week, the HonorHealth Research Institute in Scottsdale used a new technology to treat atrial fibrillation (Afib).

Ongoing proof-of-concept (PoC) clinical trial in pain associated with pancreatic cancer with topline data on track for 1H ...

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Q1 2025 Management View CEO Dave Rosa highlighted the strong performance of the OneRF ablation system, which is the first FDA-cleared product ...

Dave Rosa; President, Chief Executive Officer, Director; Neuroone Medical Technologies Corp. Ron McClurg; Chief Financial Officer; Neuroone Medical Technologies Corp ...

Reports Q1 product revenue $3.3M vs. $1M last year. Reports Q1 license revenue $3M vs. $0 last year. “This quarter marks the next step forward ...

Total revenue of $6.3M Includes $3.3 Million of Product Revenue in Addition to a One-Time Upfront Payment of $3.0 Million in License Revenue from ...

NeuroOne Medical Technologies Corporation ( NASDAQ: NMTC) Q1 2025 Earnings Conference Call February 12, 2025 8:30 AM ET ...